Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention in Females After Surgery For Pelvic Floor Disorders

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04232683

Enrollment

100

Registered

2020-01-18

Start date

2019-12-18

Completion date

2025-10-11

Last updated

2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Retention

Keywords

Female Pelvic Floor Disorders, Postoperative Urinary Retention, Tamsulosin

Brief summary

Our hypothesis is that patients receiving preoperative Tamsulosin will have decrease rates of postoperative urinary retention (POUR) after surgery in females for pelvic floor disorders.

Detailed description

This study is a prospective randomized control trial. Patients undergoing pelvic surgery will randomized into two groups. The study group will receive one oral dose of .4mg of Tamsulosin preoperatively.The control group will receive one placebo pill preoperatively. Success or failure of initial voiding trial in postoperative period will be measured. Patients who fail the voiding trial will be discharged home with Foley catheter as is standard protocol at our institution.

Interventions

DRUGTamsulosin 0.4Mg Capsule

Tamsulosin given preoperatively to detect if rates of urinary retention after female pelvic floor surgeries are decreased

DRUGPlacebo oral tablet

Placebo pill given preoperatively

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

i. Patient undergoing surgery for prolapse with or without mid-urethral sling procedure. ii. Specific surgical procedures include all vaginal, laparoscopic and robotic reconstructive or obliterative surgeries including the use of mid-urethral slings

Exclusion criteria

i. Diagnosis of urinary retention preoperatively (post void residual \>150ml) ii. Malignancy iii. History of neurological disease iv. History of spinal cord injuries v. Allergy to Tamsulosin vi. Perioperative complications requiring prolonged postoperative bladder drainage vii. Incontinence procedures other than mid-urethral slings

Design outcomes

Primary

Measure	Time frame	Description
Tamsulosin Effect	Up to 4 hours after surgery while patient is in post-anesthesia care unit.	Assess the effect of Tamsulosin in preventing POUR, defined by failure of initial voiding trial postoperatively.

Secondary

Measure	Time frame	Description
Postoperative Narcotic Use	Up to 4 hours after surgery while patient is in post-anesthesia care unit.	Amount of postoperative narcotic use will be tracked to assess if increased narcotic use has an effect on postoperative voiding trial (The amount of narctoic use will be measured in milligrams)
Effect of Tamsulosin on postoperative blood pressure	Up to 4 hours after surgery while patient is in post-anesthesia care unit	A side effect of Tamsulosin in hypotension, therefore, postoperative blood pressure will be evaluated to see if Tamsulosin had a significant impact on blood pressure

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 27, 2026